---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-011025"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2022-06-01T23:59:59+00:00"
generated_at: "2026-06-25T05:36:00.761046+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Terns Pharmaceuticals appoints Kerry Russell as Chief Medical Officer effective June 1, 2022

## Summary
- Kerry Russell, M.D., Ph.D., named CMO, reporting to President and Head of R&D Erin Quirk, M.D.
- Dr. Russell previously VP of late clinical development at Dicerna Pharmaceuticals (acquired by Novo Nordisk).
- She held leadership roles at resTORbio, Novartis, and was an NIH-funded associate professor at Yale.
- Terns expects key clinical data readouts for TERN-501, TERN-601, and TERN-701 across NASH, obesity, and CML.

## SEC filing metadata
- accession: 0000950170-22-011025
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2022-06-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017022011025/0000950170-22-011025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017022011025/tern-20220601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-011025
- JSON: https://secwatch.observer/filing/0000950170-22-011025.json
- Plain text: https://secwatch.observer/filing/0000950170-22-011025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.